bioXXmed AG
- ISIN DE000A0KFRJ1
- Country Deutschland
Company profile
In 2006, bioXXmed AG – as CytoTools AG – was founded in Darmstadt (Germany). The company is listed on the Frankfurt Stock Exchange (Basic Board) and acts as an investor in biotech companies with a focus on dermatology, in particular wound healing, by continuously increasing the share capital of the holdings. Around 48% of the shares are currently held by two long-term oriented shareholders, the rest of the shares are in free float.
bioXXmed AG has invested more than €22 million in various development projects of two associated companies and sees itself as an “active owner”. These projects included pre-clinical and clinical projects in the areas of oncology, cardiovascular, sepsis and dermatology. As a result of a strategic review last year, bioXXmed decided to focus mainly on projects in dermatology. This clinical segment offers numerous questions with an “unmet medical need”, i.e. unsatisfactory standard of care. Primary or secondary skin diseases can sometimes be treated symptomatically, but often cannot be cured.
In addition, the most advanced, marketable product, DermaPro®, is used to treat chronic wounds, particularly diabetic foot syndrome. DermaPro® from DermaTools Biotech GmbH is a patented chemical product and is applied topically. In numerous clinical studies, it has demonstrated its safety and effectiveness in reducing or healing chronic wounds in diabetics. This indication is an unsolved medical problem with a prevalence of at least 6% of all diabetics. Complications such as amputations are serious and the cost burden on healthcare systems is extreme.
The product is in final development to be approved as a medicinal product (CE registration) in Europe, expected in the course of 2023. Other markets are currently being evaluated.
bioXXmed is evaluating further projects in dermatology that would support the focus on dermatology in very relevant disease indications. bioXXmed AG has a competent team that is capable of successfully managing dermatological projects. Therefore, bioXXmed AG will provide the project partner with development and commercial know-how and take an active role in the management of such projects.
We are interested in a broader and more international base of financial investors in order to accelerate the development of such projects and thus increase the value of bioXXmed AG for our shareholders.
bioXXmed AG has invested more than €22 million in various development projects of two associated companies and sees itself as an “active owner”. These projects included pre-clinical and clinical projects in the areas of oncology, cardiovascular, sepsis and dermatology. As a result of a strategic review last year, bioXXmed decided to focus mainly on projects in dermatology. This clinical segment offers numerous questions with an “unmet medical need”, i.e. unsatisfactory standard of care. Primary or secondary skin diseases can sometimes be treated symptomatically, but often cannot be cured.
In addition, the most advanced, marketable product, DermaPro®, is used to treat chronic wounds, particularly diabetic foot syndrome. DermaPro® from DermaTools Biotech GmbH is a patented chemical product and is applied topically. In numerous clinical studies, it has demonstrated its safety and effectiveness in reducing or healing chronic wounds in diabetics. This indication is an unsolved medical problem with a prevalence of at least 6% of all diabetics. Complications such as amputations are serious and the cost burden on healthcare systems is extreme.
The product is in final development to be approved as a medicinal product (CE registration) in Europe, expected in the course of 2023. Other markets are currently being evaluated.
bioXXmed is evaluating further projects in dermatology that would support the focus on dermatology in very relevant disease indications. bioXXmed AG has a competent team that is capable of successfully managing dermatological projects. Therefore, bioXXmed AG will provide the project partner with development and commercial know-how and take an active role in the management of such projects.
We are interested in a broader and more international base of financial investors in order to accelerate the development of such projects and thus increase the value of bioXXmed AG for our shareholders.